Jeffrey Jian

Dr. Jeffrey Jian

Biochemistry, Vanderbilt University, Nashville, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Molecular Cell
Verified
Journal Article
Closed access
BKByungil Kim
Byungil Kim
SASarah Arcos
Sarah Arcos
KRKatherine Rothamel
Katherine Rothamel
JJJeffrey Jian
Jeffrey Jian
KRKristie L. Rose
Kristie L. Rose
MAManuel Ascano
Manuel Ascano

22 December 2016 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
MCMassimiliano Cristofanilli
Massimiliano Cristofanilli
DGDaniel Gratch
Daniel Gratch
BPBenjamin Pagano
Benjamin Pagano
KMKelsey McDermott
Kelsey McDermott
JHJessie Huang
Jessie Huang
SSSaud A Sadiq
Saud A Sadiq
Background: Transglutaminase-6 (TGM6), a member of the transglutaminase enzyme family, is found predominantly in central nervous system (CNS) neurons under physiological conditions. It has been proposed as an autoimmune target in cerebral palsy, gluten-sensitive cerebellar ataxia, and schizophrenia. Objective: To investigate TGM6 involvement in multiple sclerosis (MS). Methods: Antibody levels against TGM6 (TGM6-IgG) were measured in the cerebrospinal fluid (CSF) of 62 primary progressive multiple sclerosis (PPMS), 85 secondary progressive multiple sclerosis (SPMS), and 50 relapsing-remitting multiple sclerosis (RRMS) patients and 51 controls. TGM6 protein expression was analyzed in MS brain autopsy, murine experimental autoimmune encephalomyelitis (EAE), and cultured astrocytes. Results: CSF levels of TGM6-IgG were significantly higher in PPMS and SPMS compared to RRMS and controls. Notably, patients with clinically active disease had the highest TGM6-IgG levels. Additionally, brain pathology revealed strong TGM6 expression by reactive astrocytes within MS plaques. In EAE, TGM6 expression in the spinal cord correlated with disease course and localized in reactive astrocytes infiltrating white matter lesions. Finally, knocking down TGM6 expression in cultured reactive astrocytes reduced their glial fibrillary acidic protein (GFAP) expression. Conclusion: TGM6-IgG may be a candidate CSF biomarker to predict and monitor disease activity in progressive MS patients. Furthermore, TGM6 expression by reactive astrocytes within both human and mouse lesions suggests its involvement in the mechanisms of glial scar formation.

31 March 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JJJeffrey Jian
Jeffrey Jian
KMKevin D. McCarty
Kevin D. McCarty
JBJo Ann W Byl
Jo Ann W Byl
FGF Peter Guengerich
F Peter Guengerich
KNKeir C Neuman
Keir C Neuman
Neil OsheroffNeil Osheroff
Neil Osheroff
To perform double-stranded DNA passage, type II topoisomerases generate a covalent enzyme-cleaved DNA complex (i.e. cleavage complex). Although this complex is a requisite enzyme intermediate, it is also intrinsically dangerous to genomic stability. Consequently, cleavage complexes are the targets for several clinically relevant anticancer and antibacterial drugs. Human topoisomerase IIα and IIβ and bacterial gyrase maintain higher levels of cleavage complexes with negatively supercoiled over positively supercoiled DNA substrates. Conversely, bacterial topoisomerase IV is less able to distinguish DNA supercoil handedness. Despite the importance of supercoil geometry to the activities of type II topoisomerases, the basis for supercoil handedness recognition during DNA cleavage has not been characterized. Based on the results of benchtop and rapid-quench flow kinetics experiments, the forward rate of cleavage is the determining factor of how topoisomerase IIα/IIβ, gyrase and topoisomerase IV distinguish supercoil handedness in the absence or presence of anticancer/antibacterial drugs. In the presence of drugs, this ability can be enhanced by the formation of more stable cleavage complexes with negatively supercoiled DNA. Finally, rates of enzyme-mediated DNA ligation do not contribute to the recognition of DNA supercoil geometry during cleavage. Our results provide greater insight into how type II topoisomerases recognize their DNA substrates.